Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma

Morita,Yoshihiro; Hata,Kenji; Nakanishi,Masako; Nishisho,Toshihiko; Yura,Yoshiaki; Yoneda,Toshiyuki

doi:10.3892/ijo.2012.1529

Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma

Authors:
- Yoshihiro Morita
- Kenji Hata
- Masako Nakanishi
- Toshihiko Nishisho
- Yoshiaki Yura
- Toshiyuki Yoneda
View Affiliations

Affiliations: Department of Molecular and Cellular Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan, Department of Oral and Maxillofacial Surgery II, Osaka University Graduate School of Dentistry, Osaka, Japan
Published online on: June 25, 2012 https://doi.org/10.3892/ijo.2012.1529
Pages: 885-892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral squamous cell carcinoma (OSCC) is the sixth most common cancer and frequently metastasizes to the cervical lymph nodes, leading to poor survival of patients with OSCC. However, the mechanism of lymph node metastasis is not fully understood. To clarify the molecular mechanism underlying OSCC metastasis to regional lymph nodes, the highly metastatic fluorescent labeled OSCC cell line SAS-LM3 was successfully established allowing us to monitor the progression of lymph node metastases in a non-invasive manner. SAS-LM3 tumors showed increased lymphangiogenesis and elevated expression of VEGF-C, a potent stimulator of lymphangiogenesis, compared to parental SAS tumors. SAS-LM3 showed high expression of cyclooxygenase-2 (COX-2) compared to parental SAS cells and immunohistochemical analysis demonstrated intense COX-2 expression at the primary site. Inactivation of COX-2 by knockdown or the COX-2 inhibitor NS-398 decreased VEGF-C expression. Administration of COX-2 inhibitor NS-398 in SAS-LM3 tumor-bearing mice suppressed tumor lymphangiogenesis and lymphatic metastases. Collectively, our results indicate that COX-2 promotes tumor lymphangiogenesis and lymph node metastasis of OSCC. COX-2 ablation holds promise as a potential therapeutic approach for lymph node metastasis in OSCC.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Hunter KD, Parkinson EK and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer. 5:127–135. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900. 2001. View Article : Google Scholar
4.	Gil Z, Carlson DL, Boyle JO, et al: Lymph node density is a significant predictor of outcome in patients with oral cancer. Cancer. 115:5700–5710. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A and Bosq J: Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg. 168:494–498. 1994. View Article : Google Scholar : PubMed/NCBI
6.	Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:17511996.
7.	Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672–682. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Stacker SA, Caesar C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 7:186–191. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Sleeman JP and Thiele W: Tumor metastasis and the lymphatic vasculature. Int J Cancer. 125:2747–2756. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Makinen T, Veikkola T, Mustjoki S, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20:4762–4773. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Roberts N, Kloos B, Cassella M, et al: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66:2650–2657. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Shimizu K, Kubo H, Yamaguchi K, et al: Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95:328–333. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Veikkola T, Jussila L, Makinen T, et al: Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20:1223–1231. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Burton JB, Priceman SJ, Sung JL, et al: Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 68:7828–7837. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Alitalo K and Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1:219–227. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Dadras SS, Paul T, Bertoncini J, et al: Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 162:1951–1960. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Karpanen T and Alitalo K: Lymphatic vessels as targets of tumor therapy? J Exp Med. 194:F37–F42. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Wu KK: Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol. 33:179–207. 1995. View Article : Google Scholar : PubMed/NCBI
20.	Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 94:3336–3340. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Vane JR, Mitchell JA, Appleton I, et al: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA. 91:2046–2050. 1994. View Article : Google Scholar : PubMed/NCBI
22.	Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 1470:M69–M78. 2000.PubMed/NCBI
23.	Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:803–809. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Fujita T, Matsui M, Takaku K, et al: Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 58:4823–4826. 1998.PubMed/NCBI
25.	Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 93:497–506. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:705–716. 1998. View Article : Google Scholar : PubMed/NCBI
27.	Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 105:1589–1594. 2000. View Article : Google Scholar : PubMed/NCBI
28.	Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
29.	Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:1306–1311. 2000.PubMed/NCBI
30.	Takahashi K, Kanazawa, Akiyama, et al: Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc. 38:20–28. 1989.
31.	Shintani S, Mihara M, Nakahara Y, et al: Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression. Oral Oncol. 38:664–669. 2002. View Article : Google Scholar : PubMed/NCBI
32.	Iwata C, Kano MR, Komuro A, et al: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 67:10181–10189. 2007. View Article : Google Scholar : PubMed/NCBI
33.	Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:3761–3764. 1998.PubMed/NCBI
34.	Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1276–1280. 1997.PubMed/NCBI
35.	Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:3785–3789. 1995.PubMed/NCBI
36.	Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
37.	Choe MS, Zhang X, Shin HJ, Shin DM and Chen ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther. 4:1448–1455. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Mendes RA, Carvalho JF and Waal I: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol. 45:e124–e128. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Da MX, Wu XT, Wang J, et al: Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 39:92–99. 2008. View Article : Google Scholar : PubMed/NCBI
40.	Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64:554–564. 2004. View Article : Google Scholar : PubMed/NCBI
41.	Zhang XH, Huang DP, Guo GL, et al: Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer. 8:42008. View Article : Google Scholar : PubMed/NCBI
42.	Di JM, Zhou J, Zhou XL, et al: Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res. 40:268–275. 2009. View Article : Google Scholar : PubMed/NCBI
43.	Oka M, Iwata C, Suzuki HI, et al: Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood. 111:4571–4579. 2008. View Article : Google Scholar : PubMed/NCBI
44.	Zwaans BM and Bielenberg DR: Potential therapeutic strategies for lymphatic metastasis. Microvasc Res. 74:145–158. 2007. View Article : Google Scholar : PubMed/NCBI
45.	Burton JB, Johnson M, Sato M, et al: Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med. 14:882–888. 2008. View Article : Google Scholar : PubMed/NCBI
46.	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
47.	Wendt MK, Allington TM and Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 5:1145–1168. 2009. View Article : Google Scholar : PubMed/NCBI